Frost & Sullivan is ranked among the "Top 5 Most Trusted Healthcare Service Providers of 2023"

The 'Annual China Healthcare Industry Investment and Financing Honor Roll' is an authoritative third-party list in the healthcare sector, based on a comprehensive review of the current investment and financing development of the healthcare industry. It uses multiple criteria such as institutional activity, number of investment projects, outstanding cases, investment returns, total managed capital, corporate financing and development status, and valuation to select the top 15 awards across five categories: Investment Institutions, Enterprises, Services, Parks, and Individuals. The list is selected based on the principles of fairness and justice, aiming to recognize and reward the best in each category.

Since the release of the first list in 2018, the Honor Roll has become one of the important benchmarks for the development and investment financing of China's healthcare industry. The release of the Honor Roll is not only an acknowledgment and affirmation of the value contributors to the healthcare industry but also an encouragement and motivation for the entire industry, reflecting the positive values and energy within the sector.

Frost & Sullivan (Frost & Sullivan, abbreviated as "Frost & Sullivan") safeguards the development of clients with its excellent service quality, profound professional competence, and exquisite practice skills. It provides efficient and high-quality professional services for the healthcare industry and has been listed among the "Top 5 Most Trusted Healthcare Service Providers of 2023" for its outstanding team performance.

Frost & Sullivan, integrating 63 years of global consulting experience, has dedicated 26 years to serving the booming Chinese market. With a global perspective, it helps clients accelerate their business growth, achieving industry-leading benchmarks in terms of growth, innovation, and leadership. The big health industry is one of the core areas of focus for Frost & Sullivan.

Frost & Sullivan has professional analytical capabilities and extensive project experience in the field of life sciences. Leveraging Frost & Sullivan's global think tank resources and cross-industry business development platform in Greater China, it has unique core advantages in investment and financing services for the life science industry. Frost & Sullivan has a wide range of corporate clients in China, having established a vast client network over the past 20 years and accumulated extensive project experience in various sub-sectors of life sciences. Project types include knowledge center projects (in-depth content, promotional activities), Pre-IPO projects (DCF valuation, business plan services), IPO listing projects (industry advisory, clinical audit, fundraising and investment writing), market research, market value management, and strategic consulting, etc. It also collaborates with well-known domestic and international information platforms and investment and financing institutions to provide one-stop solutions for enterprises in specialized sub-sectors such as pharmaceuticals and medical devices, attracting widespread attention from investors.

As an industry advisor, Frost & Sullivan has become the preferred partner for healthcare companies seeking to list in Hong Kong and overseas with its exceptional services. According to publicly disclosed information from the Hong Kong Exchange, from 2015 to 2023, Frost & Sullivan maintained a leading position in the Hong Kong stock market's listed advisory segment for nine consecutive years, accounting for the largest proportion of listed companies in the sector. It is an absolute leader in serving healthcare companies seeking to list in Hong Kong. In addition, since the first batch of companies on the Sci-Tech Innovation Board (STAR Market) was listed in July 2019, Frost & Sullivan reports have been widely cited in the prospectuses of leading STAR Market-listed companies, accounting for up to 75% of the market share.

Since 2018, Frost & Sullivan has continuously published multiple industry blue books in the field of life sciences, such as 'Blue Book on the Current Development and Future Trends of Medical Beauty Injection Products', 'Blue Book on the Current Situation and Future Development Trends of High-End Ophthalmic Medical Equipment', 'Blue Book on the Development of Tumor Molecular Diagnostics Industry', 'Blue Book on the Current Situation and Development Trends of Vascular Interventional Special Balloons', 'Blue Book on the Current Situation and Future Development of China's Radioactive Drug Industry', 'Blue Book on the Current Situation and Development Trends of Gene Drugs Industry', 'Blue Book on the Development of Hong Kong's 18A & Sci-Tech Innovation Board Biotechnology Industry in 2023', etc. These books deeply analyze the current development status and future trends of various sub-industries, providing valuable reference perspectives for market investors.

In the future, Frost & Sullivan will continue to increase its investment and focus on the life sciences field, actively explore new service and business models, pay attention to policy changes and market demands in this area, and provide clients with more professional and efficient consulting services. We hope to work with more healthcare enterprises to understand industry trends, seize development opportunities, jointly promote the prosperity and development of China's healthcare industry, and contribute to the cause of human health.